Journal
CURRENT ORTHOPAEDIC PRACTICE
Volume 24, Issue 4, Pages 424-432Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BCO.0b013e31828e68b7
Keywords
anticoagulant; antithrombotic; venous thromboembolism; total knee arthroplasty; neuraxial blockade
Categories
Funding
- Janssen Scientific Affairs, LLC, Raritan, NJ
Ask authors/readers for more resources
Patients who undergo total knee arthroplasty are at risk of developing venous thromboembolism. Thromboprophylaxis is widely accepted as standard of care in patients receiving total knee arthroplasty, but implementation of clinical practice guidelines is hampered by several barriers, including limitations of current agents. New anticoagulants in clinical development offer equivalent or superior efficacy and safety to existing anticoagulants and the added convenience of oral administration. To date, rivaroxaban is the only new oral anticoagulant with regulatory approval for total knee arthroplasty in the United States, although dabigatran and apixaban are approved in other countries. For total knee arthroplasty, neuraxial blockade offers advantages over general anesthesia and narcotic-based systemic analgesia, but it carries a risk of spinal hematoma if used in conjunction with antithrombotics. Clinical practice guidelines already exist for the use of neuraxial blockade with traditional antithrombotics, and similar evidence-based recommendations are required for the new oral anticoagulants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available